{"id":"lacosamide","brandName":"Vimpat","genericName":"lacosamide","companyId":"ucb","companyName":"UCB","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":0,"mechanism":{"target":"Dihydropyrimidinase-related protein 2, Carbonic anhydrase 1, Carbonic anhydrase 12","_target_confidence":0.5},"administration":{"route":"Intravenous"},"safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"SEIZURE","source":"FDA FAERS","actionTaken":"6507 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"3936 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"3757 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"1611 reports"},{"date":"","signal":"SOMNOLENCE","source":"FDA FAERS","actionTaken":"1404 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1374 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"1337 reports"},{"date":"","signal":"EPILEPSY","source":"FDA FAERS","actionTaken":"1336 reports"},{"date":"","signal":"STATUS EPILEPTICUS","source":"FDA FAERS","actionTaken":"1220 reports"},{"date":"","signal":"OVERDOSE","source":"FDA FAERS","actionTaken":"1207 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Diplopia","drugRate":"","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Somnolence","drugRate":"","severity":"common","organSystem":""},{"effect":"Injection site pain or discomfort","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Paresthesia","drugRate":"","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"","severity":"common","organSystem":""},{"effect":"Dry mouth","drugRate":"","severity":"common","organSystem":""},{"effect":"Cognitive disorder","drugRate":"","severity":"common","organSystem":""},{"effect":"Hypoaesthesia","drugRate":"","severity":"common","organSystem":""},{"effect":"Dysarthria","drugRate":"","severity":"common","organSystem":""},{"effect":"Disturbance in attention","drugRate":"","severity":"common","organSystem":""},{"effect":"Irritability","drugRate":"","severity":"common","organSystem":""},{"effect":"Confusional state","drugRate":"","severity":"common","organSystem":""},{"effect":"Mood altered","drugRate":"","severity":"common","organSystem":""},{"effect":"Depressed mood","drugRate":"","severity":"common","organSystem":""},{"effect":"Injection site irritation","drugRate":"1%","severity":"common","organSystem":""},{"effect":"Injection site erythema","drugRate":"0.5%","severity":"common","organSystem":""}],"contraindications":["Acute nephropathy","Atrial fibrillation","Atrial flutter","Chronic heart failure","Complete atrioventricular block","Disease of liver","Disorder of coronary artery","First Degree Atrioventricular Heart Block","Myocardial ischemia","Orthostatic hypotension","Second degree atrioventricular block","Severe Cardiac Disease","Sick sinus syndrome","Suicidal","Suicidal thoughts"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Suicidal Behavior and Ideation","drugRate":"","severity":"serious"},{"effect":"Ataxia","drugRate":"","severity":"serious"},{"effect":"Cardiac Rhythm and Conduction Abnormalities","drugRate":"","severity":"serious"},{"effect":"Syncope","drugRate":"","severity":"serious"},{"effect":"Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)/Multiorgan Hypersensitivity Reactions","drugRate":"","severity":"serious"},{"effect":"Elevated ALT (≥3x ULN)","drugRate":"0.7%","severity":"serious"},{"effect":"Hepatitis with transaminases >20x ULN","drugRate":"","severity":"serious"},{"effect":"Nephritis","drugRate":"","severity":"serious"},{"effect":"Profound Bradycardia","drugRate":"","severity":"serious"},{"effect":"Cerebellar syndrome","drugRate":"","severity":"serious"}]},"trials":["NCT05598905","NCT01458522","NCT05291455","NCT02710890","NCT01465997","NCT01484977","NCT01724918","NCT05263674","NCT00530855","NCT02409433","NCT03777956","NCT00938912","NCT02374567","NCT04519645","NCT00440518","NCT01986608","NCT01375387","NCT01110187","NCT05851781","NCT02408523","NCT06081283","NCT01190098","NCT02124564","NCT00955357","NCT01530022","NCT03204474","NCT03436433","NCT05940935","NCT02726867","NCT05788159","NCT06243692","NCT00235443","NCT05626140","NCT04144218","NCT00800215","NCT01796938","NCT04737837","NCT01969851","NCT03559673","NCT06485726","NCT02582866","NCT02342977","NCT01964560","NCT02192814","NCT00350103","NCT06866691","NCT01118949","NCT05422664","NCT02276053","NCT01530386"],"indications":{"approved":[{"name":"Idiopathic generalized epilepsy","diseaseId":"idiopathic-generalized-epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Partial Epilepsy Treatment Adjunct","diseaseId":"partial-epilepsy-treatment-adjunct","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Tonic-clonic seizure in patients with epilepsy","diseaseId":"tonic-clonic-seizure-in-patients-with-epilepsy","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":null,"patents":[{"type":"Formulation","number":"11337943","applicant":"AUCTA PHARMACEUTICALS INC","territory":"US","tradeName":"MOTPOLY XR","expiryDate":"2040-06-05"},{"type":"Formulation","number":"12042474","applicant":"AUCTA PHARMACEUTICALS INC","territory":"US","tradeName":"MOTPOLY XR","expiryDate":"2040-06-05"},{"type":"Formulation","number":"11883374","applicant":"AUCTA PHARMACEUTICALS INC","territory":"US","tradeName":"MOTPOLY XR","expiryDate":"2040-06-05"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT05598905","phase":"Phase 4","title":"Combined Effect of Pregabalin and Oxycodone, and Lacosamide and Oxycodone, on Breathing: an Exploratory Study in Healthy Volunteers (The Polo Study)","status":"COMPLETED","sponsor":"Leiden University Medical Center","isPivotal":false,"enrollment":24,"indication":"Opioid-induced Respiratory Depression","completionDate":"2024-01-12"},{"nctId":"NCT01458522","phase":"Phase 2","title":"Utility of Intravenous Lacosamide Compared With Fosphenytoin in the Treatment of Patients With Frequent Nonconvulsive Seizures","status":"COMPLETED","sponsor":"Aatif Husain","isPivotal":false,"enrollment":74,"indication":"Nonconvulsive Seizures","completionDate":"2015-07"},{"nctId":"NCT05291455","phase":"Phase 3","title":"Efficacy of Lacosamide in Neonatal Status Epilepticus: A Randomized Controlled Study","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","isPivotal":true,"enrollment":60,"indication":"Epilepsy","completionDate":"2024-04-01"},{"nctId":"NCT02710890","phase":"Phase 2","title":"A Multicenter, Open-Label Study to Investigate the Safety and Tolerability of Intravenous Lacosamide in Children (>= 1 Month to < 17 Years of Age) With Epilepsy","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","isPivotal":true,"enrollment":103,"indication":"Epilepsy","completionDate":"2019-06-28"},{"nctId":"NCT01465997","phase":"Phase 3","title":"A Multicenter, Double-blind, Double-dummy, Follow up Study Evaluating the Long-term Safety of Lacosamide in Comparison With Controlled-release Carbamazepine Used as Monotherapy in Subjects With Partia","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","isPivotal":true,"enrollment":551,"indication":"Epilepsy, Monotherapy","completionDate":"2017-01"},{"nctId":"NCT01484977","phase":"Phase 3","title":"Open-label, Single Arm, Study Evaluating Tolerability and Efficacy of Lacosamide When Added to Levetiracetam With Withdrawal of Concomitant Sodium Channel Blocking Antiepileptic Drug in Subjects With ","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":120,"indication":"Epilepsy","completionDate":"2013-12"},{"nctId":"NCT01724918","phase":"Phase 2","title":"Lacosamide IV and EEG/EKG (LIVE) Study","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","isPivotal":false,"enrollment":72,"indication":"Focal Epilepsy","completionDate":"2016-08"},{"nctId":"NCT05263674","phase":"Phase 3","title":"Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial)","status":"RECRUITING","sponsor":"University of Southern Denmark","isPivotal":true,"enrollment":140,"indication":"Non-Convulsive Status Epilepticus","completionDate":"2028-12-31"},{"nctId":"NCT00530855","phase":"Phase 3","title":"A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects With Partial-onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":322,"indication":"Epilepsy","completionDate":"2014-12"},{"nctId":"NCT02409433","phase":"Phase 4","title":"Prospective, Randomized, Single-blinded Comparative Trial of IV Lacosamide Versus Phenytoin for Seizure Management","status":"TERMINATED","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","isPivotal":false,"enrollment":3,"indication":"Seizures","completionDate":"2015-11"},{"nctId":"NCT03777956","phase":"Phase 2","title":"The Effect of Lacosamide in Peripheral Neuropathic Pain: a Randomized, Double-blind, Placebo Controlled, Phenotype-stratified Study","status":"TERMINATED","sponsor":"Danish Pain Research Center","isPivotal":false,"enrollment":63,"indication":"Neuropathic Pain, Neuropathy;Peripheral","completionDate":"2022-06-03"},{"nctId":"NCT00938912","phase":"Phase 2","title":"An Open-Label Study To Determine Safety, Tolerability And Efficacy Of Long -Term Oral Lacosamide (LCM) As Adjunctive Therapy In Children With Epilepsy","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","isPivotal":false,"enrollment":366,"indication":"Epilepsy","completionDate":"2021-05-18"},{"nctId":"NCT02374567","phase":"Phase 3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","isPivotal":true,"enrollment":407,"indication":"Dementia, Depression","completionDate":"2017-06-28"},{"nctId":"NCT04519645","phase":"Phase 2","title":"A Multicenter, Open-Label, Randomized, Active Comparator Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures","status":"TERMINATED","sponsor":"UCB Biopharma SRL","isPivotal":false,"enrollment":29,"indication":"Electroencephalographic Neonatal Seizures, Epilepsy","completionDate":"2024-10-31"},{"nctId":"NCT00440518","phase":"Phase 2","title":"A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 100mg/Day and 300mg/Day Lacosamide for Migraine Prophylaxis.","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":false,"enrollment":218,"indication":"Migraine","completionDate":"2008-07"},{"nctId":"NCT01986608","phase":"Phase 1","title":"A Single Center Open-label, Randomized, Single-dose, 3-way Crossover Study to Compare the Safety, Tolerability, and Pharmacokinetics of Lacosamide Administered as Oral Tablet or Intravenous Infusion i","status":"COMPLETED","sponsor":"UCB Pharma SA","isPivotal":false,"enrollment":26,"indication":"Healthy Volunteers","completionDate":"2013-12"},{"nctId":"NCT01375387","phase":"Phase 1","title":"A Phase I, Randomized Double-blind, Placebo-controlled, Single-center, Single-dose, Three-way Cross-over Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Lacosamide Tablets in Healt","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":false,"enrollment":33,"indication":"Healthy Volunteers","completionDate":"2011-06"},{"nctId":"NCT01110187","phase":"NA","title":"A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","isPivotal":false,"enrollment":11,"indication":"Traumatic Brain Injury","completionDate":"2012-05"},{"nctId":"NCT05851781","phase":"Phase 3","title":"Safety and Efficacy of Lacosamide Versus Propranolol in Migraine","status":"COMPLETED","sponsor":"Kafrelsheikh University","isPivotal":true,"enrollment":600,"indication":"Migraine Disorders","completionDate":"2023-08-30"},{"nctId":"NCT02408523","phase":"Phase 3","title":"A Double-blind, Randomized, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clo","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","isPivotal":true,"enrollment":242,"indication":"Epilepsy","completionDate":"2019-06"},{"nctId":"NCT06081283","phase":"Phase 4","title":"Effect of Antiseizure Medication in Seizure Networks at Early Stages of Acute Brain Injury. The Rs-fMRI, Open-label Pilot Trial","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","isPivotal":false,"enrollment":5,"indication":"Brain Injuries, Acute, Brain Injuries, Traumatic","completionDate":"2025-01-22"},{"nctId":"NCT01190098","phase":"Phase 4","title":"Searching for \"Sleep Friendly\" Therapies for a Sleepy Population: A Double-Blind, Placebo-Controlled, Randomized Trial to Assess the Effects of Lacosamide on Sleep and Wake in Adults With Focal Epilep","status":"COMPLETED","sponsor":"The Cleveland Clinic","isPivotal":false,"enrollment":59,"indication":"Partial Epilepsy","completionDate":"2014-11"},{"nctId":"NCT02124564","phase":"Phase 3","title":"Multicenter, Open-Label, Long-Term Study to Investigate the Safety of Conversion to Lacosamide at Doses up to 600 mg/Day as Monotherapy in Japanese Adults With Partial-Onset Seizures With or Without S","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","isPivotal":true,"enrollment":19,"indication":"Epilepsy, Partial-onset Seizures","completionDate":"2017-11-21"},{"nctId":"NCT00955357","phase":"Phase 4","title":"An Open-Label, Multicenter, Multinational Study of Lacosamide as First Add-On Anti-epileptic Drug (AED) Treatment in Subjects With Partial-Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":false,"enrollment":461,"indication":"Partial Epilepsies","completionDate":"2013-08"},{"nctId":"NCT01530022","phase":"Phase 1","title":"A Multicenter, Randomized, Double-blind, Double-dummy, 2-period Crossover Study of Neuropsychological Effects of Lacosamide and Carbamazepine Immediate Release in Healthy Subjects","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":false,"enrollment":60,"indication":"Healthy","completionDate":"2014-01"},{"nctId":"NCT03204474","phase":"Phase 1","title":"A Randomized, Open-Label, Single-Dose, 2-Way Crossover Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","isPivotal":false,"enrollment":30,"indication":"Healthy Male Chinese Volunteers","completionDate":"2017-07-28"},{"nctId":"NCT03436433","phase":"Phase 2","title":"Phase II Trial of Seizure Prophylaxis in Brain Tumor Patients Undergoing Neurosurgical Procedure","status":"TERMINATED","sponsor":"Duke University","isPivotal":false,"enrollment":4,"indication":"Glioma, Glioma of Brain","completionDate":"2020-12-04"},{"nctId":"NCT05940935","phase":"N/A","title":"The Relationship of Developing Metabolic Acidosis With Antiepleptic Drugs in Craniotomy Operations; Does Topiramat or Zonisamide Cause Metabolic Acidosis?","status":"COMPLETED","sponsor":"Trakya University","isPivotal":false,"enrollment":35,"indication":"Metabolic Acidosis, Antiepileptic Drugs","completionDate":"2023-08-15"},{"nctId":"NCT02726867","phase":"Phase 3","title":"Evaluation of Efficacy and Safety of Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus","status":"WITHDRAWN","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","isPivotal":true,"enrollment":0,"indication":"Epilepsy, Status Epilepticus","completionDate":"2016-11"},{"nctId":"NCT05788159","phase":"Phase 1","title":"An Open Label, Balanced, Randomized, Two-Treatment, Two-Period, Two-Sequence, Two-way Crossover, Oralcomparative Pharmacokinetic（PK）Study of Lacosamide Extended-Release Tablets , Adult, Human Subjects","status":"UNKNOWN","sponsor":"Overseas Pharmaceuticals, Ltd.","isPivotal":false,"enrollment":16,"indication":"Epilepsy","completionDate":"2023-07-31"},{"nctId":"NCT06243692","phase":"Phase 3","title":"Lacosamide Versus Topiramate in Migraine, a Ranodmized Trial","status":"UNKNOWN","sponsor":"Kafrelsheikh University","isPivotal":true,"enrollment":600,"indication":"Migraine Disorders","completionDate":"2025-02-25"},{"nctId":"NCT00235443","phase":"Phase 2","title":"A Multi-Center, Open-Label, Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Subjects With Painful Distal Diabetic Neuropathy","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":451,"indication":"Diabetic Neuropathy","completionDate":"2008-07"},{"nctId":"NCT05626140","phase":"Phase 3","title":"COMPARISON OF EFFICACY OF DICLOFENAC VERSUS DICLOFENAC PLUS CODEINE AND DICLOFENAC PLUS LACOSAMIDE IN ACUTE SCIATICA","status":"COMPLETED","sponsor":"Pakistan Institute of Medical Sciences","isPivotal":true,"enrollment":120,"indication":"Sciatica Acute, Sciatica","completionDate":"2022-07-31"},{"nctId":"NCT04144218","phase":"Phase 4","title":"International Multicenter, Double-blind, Randomized, Placebo-controlled Evaluation of the Efficacy and Safety of Lacosamide in the Treatment of Pediatric Patients With Focal Refractory Epilepsy.","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":300,"indication":"Epilepsy","completionDate":"2021-12"},{"nctId":"NCT00800215","phase":"Phase 2","title":"A Multicenter, Double-blind, Double-dummy, Randomized Trial to Investigate the Safety, Tolerability and Pharmacokinetics of Intravenous SPM 927 as Replacement for Oral SPM 927 in Subjects With Partial","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":false,"enrollment":60,"indication":"Epilepsy","completionDate":"2004-11-30"},{"nctId":"NCT01796938","phase":"Phase 1","title":"Open, Non-randomized, Sequential Group Comparison to Investigate the Pharmacokinetics, Safety, and Tolerability of 100 mg SPM 927 in Male and Female Subjects With Renal Impairment Including Subjects R","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","isPivotal":false,"enrollment":40,"indication":"Healthy, Renal Impairment","completionDate":"2004-11"},{"nctId":"NCT04737837","phase":"N/A","title":"A Multi-center,Open-label Real-world Study to Evaluate the Efficacy and Pharmaco-economics of Lacosamide as First Add-on Therapy for Adults and Children With Focal Onset Seizures","status":"UNKNOWN","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","isPivotal":false,"enrollment":200,"indication":"Epilepsy, Focal-Onset Seizure","completionDate":"2022-02-28"},{"nctId":"NCT01969851","phase":"Phase 2","title":"A MULTI-CENTER, OPEN-LABEL, EXPLORATORY STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LACOSAMIDE AS ADJUNCTIVE THERAPY IN SUBJECTS ≥1 MONTH TO <18 YEARS WITH EPILEPSY SYNDROMES ASSOCIATED WITH GENER","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":false,"enrollment":55,"indication":"Epilepsy","completionDate":"2018-04-10"},{"nctId":"NCT03559673","phase":"N/A","title":"Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic Seizures ≥16 Years of Age Coming From the SP0994 Study","status":"NO_LONGER_AVAILABLE","sponsor":"UCB Biopharma S.P.R.L.","isPivotal":false,"enrollment":0,"indication":"Epilepsies, Partial","completionDate":""},{"nctId":"NCT06485726","phase":"Phase 4","title":"Valproate Versus Propranolol in Migraine, a Randomized Controlled Trial","status":"RECRUITING","sponsor":"Kafrelsheikh University","isPivotal":false,"enrollment":600,"indication":"Migraine Disorders","completionDate":"2024-07-05"},{"nctId":"NCT02582866","phase":"Phase 3","title":"A Multicenter, Open-label, Follow-up Study to Assess the Long-term Use of Lacosamide (Flexible Dose From 200 to 600 mg/Day) Used as Monotherapy in Subjects Who Completed SP0994 and Received Lacosamide","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","isPivotal":true,"enrollment":106,"indication":"Epilepsy","completionDate":"2020-01"},{"nctId":"NCT02342977","phase":"Phase 2","title":"Effects of Lacosamide on Post-operative Opioid Requirements After a Total Hip Arthroplasty: A Randomized Double -Blinded, Placebo-controlled Pilot Study.","status":"WITHDRAWN","sponsor":"Indiana University School of Medicine","isPivotal":false,"enrollment":0,"indication":"Osteoarthritis, Rheumatoid Arthritis","completionDate":"2016-08"},{"nctId":"NCT01964560","phase":"Phase 3","title":"A Multicenter, Open-label, Long-term Extension Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive Therapy in Pediatric Subjects With Epilepsy With Partial-Onset Seizures","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","isPivotal":true,"enrollment":540,"indication":"Epilepsy","completionDate":"2022-04-13"},{"nctId":"NCT02192814","phase":"Phase 3","title":"A Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Intravenous Lacosamide as Replacement for Oral Lacosamide in Japanese Adults With Partial-onset Seizures With or Without Seco","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","isPivotal":true,"enrollment":9,"indication":"Epilepsy, Partial-onset Seizures","completionDate":"2014-12"},{"nctId":"NCT00350103","phase":"Phase 3","title":"A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of 400mg/Day Lacosamide in Subjects With Painful Distal Diabetic Neuropathy Using Two Different Tit","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":true,"enrollment":551,"indication":"Painful Diabetic Neuropathy","completionDate":"2007-06-29"},{"nctId":"NCT06866691","phase":"Phase 4","title":"Comparison of Levetiracetam Versus Lacosamide for Seizure Prevention in Moderate to Severe Traumatic Brain Injured Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","isPivotal":false,"enrollment":600,"indication":"Traumatic Brain Injury","completionDate":"2027-04"},{"nctId":"NCT01118949","phase":"Phase 2","title":"An Open-Label Pilot Study to Assess the Safety of Oral Lacosamide as Adjunctive Therapy for Uncontrolled Primary Generalized Tonic-Clonic Seizures in Subjects With Idiopathic Generalized Epilepsy","status":"COMPLETED","sponsor":"UCB BIOSCIENCES, Inc.","isPivotal":false,"enrollment":49,"indication":"Epilepsy","completionDate":"2011-08"},{"nctId":"NCT05422664","phase":"N/A","title":"A Multicenter Clinical Study of Acute Sympotomatic Seizure Secondary to Autoimmune Encephalitis and Autoimmune-associated Epilepsy","status":"UNKNOWN","sponsor":"Liu Yonghong","isPivotal":false,"enrollment":500,"indication":"Autoimmune Encephalitis, Epilepsy","completionDate":"2025-12-31"},{"nctId":"NCT02276053","phase":"N/A","title":"A Noninterventional Study of Vimpat® (Lacosamide) as Adjunctive Antiepileptic Drug Therapy in Patients With Brain Tumor-related Epilepsy","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","isPivotal":false,"enrollment":93,"indication":"Brain Tumor Related Epilepsy (BTRE)","completionDate":"2017-12-04"},{"nctId":"NCT01530386","phase":"Phase 1","title":"A Multicenter, Open-label Study to Determine the Effects of Lacosamide on Sleep in Healthy Subjects","status":"COMPLETED","sponsor":"UCB Pharma","isPivotal":false,"enrollment":25,"indication":"Healthy Subjects","completionDate":"2012-07"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.1271/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$46","description":"LACOSAMIDE 10 MG/ML SOLUTION","retrievedDate":"2026-04-07"}],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2022-03-17T00:00:00.000Z","mah":"AMNEAL PHARMS","brand_name_local":null,"application_number":"ANDA204857"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-12-22T00:00:00.000Z","mah":"MSN","brand_name_local":null,"application_number":"ANDA215379"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-10-09T00:00:00.000Z","mah":"SOMERSET THERAPS LLC","brand_name_local":null,"application_number":"ANDA214960"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-11-14T00:00:00.000Z","mah":"ACELLA","brand_name_local":null,"application_number":"ANDA218464"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-07-21T00:00:00.000Z","mah":"ZYDUS PHARMS","brand_name_local":null,"application_number":"ANDA209465"},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":"EMEA/H/C/000863"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Vimpat","application_number":null}],"patentsNormalised":[{"patent_number":"11337943","territory":"US","patent_type":"Formulation","expiry_date":"2040-06-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12042474","territory":"US","patent_type":"Formulation","expiry_date":"2040-06-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11883374","territory":"US","patent_type":"Formulation","expiry_date":"2040-06-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":7,"withResults":4},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=lacosamide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:19:24.504880+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:19:24.502728+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:19:32.206501+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:19:23.128761+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=lacosamide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:19:33.086521+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:22.075947+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:22.075993+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:19:34.645389+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Sodium channel alpha subunit blocker","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:33.704060+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL58323/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:19:33.589838+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA214960","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:19:22.076000+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:19:39.641962+00:00","fieldsConflicting":1,"overallConfidence":0.8},"crossReferences":{"chemblId":"CHEMBL58323"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}